Product Description
Mechanisms of Action: RR Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer|Brain Cancer
Phase 2: Glioblastoma|Glioma|Non-Small-Cell Lung Cancer|Multiple Myeloma|Lymphoma, Non-Hodgkin|Gliosarcoma|Brain Cancer|Melanoma|Breast Cancer|Chronic Lymphoid Leukemia|Renal Cell Carcinoma|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Adenocarcinoma|Brain Stem Cancer
Phase 1: Oligodendroglioma|Glioblastoma|Astrocytoma|Breast Cancer|Prostate Cancer|Glioma|Myelodysplastic-Myeloproliferative Diseases|Intestinal Diseases|Lymphoma|Colorectal Cancer|Rectal Diseases|Multiple Myeloma|Plasmacytoma|Head and Neck Cancer|Laryngeal Cancer|Prostatic Diseases|Intestinal Cancer|Oropharyngeal Cancer|Non-Small-Cell Lung Cancer|Myeloproliferative Disorders|Breast Diseases|Bronchogenic Carcinoma|Gastrointestinal Cancer|Leukemia, Plasma Cell|Squamous Cell Carcinoma|Lung Cancer|Hypopharyngeal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| A6701QIBA | N/A |
Unknown status |
Prostate Cancer |
2022-12-01 |
|
| NCI-2009-01092 | P2 |
Completed |
Gliosarcoma|Glioblastoma |
2011-02-16 |
|
| NCI-2012-01829 | P2 |
Completed |
Glioma |
2010-04-01 |
|
| PCYC-0222 | P2 |
Terminated |
Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Chronic Lymphoid Leukemia |
2010-02-01 |